{"nctId":"NCT00549939","briefTitle":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","startDateStruct":{"date":"2007-10"},"conditions":["Neurogenic Urinary Bladder"],"count":172,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Alfuzosin 0.1 mg/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]},{"label":"Alfuzosin 0.2 mg/kg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Alfuzosin"]}],"interventions":[{"name":"Alfuzosin","otherNames":["SL770499"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with elevated detrusor Leak Point Pressure (LPP) of neuropathic etiology and Detrusor LPP ≥ 40 cm H2O and \\< 100 cm H2O.\n\nExclusion Criteria:\n\n* Urological surgery in the last 4 months prior to the study,\n* Patients who have urethral dilatation in the last 3 months prior to the baseline urodynamic assessment,\n* α-blocker therapy in the last 4 weeks prior to the baseline urodynamic assessment,\n* Detrusor injections of botulinum toxin in the last 6 months,\n* Urological diseases/conditions other than functional bladder obstruction of neuropathic etiology that can lead to upper urinary tract dilatation (e.g., bladder anomalies, ureterocele),\n* History of intolerance to α-blocker therapy,\n* Orthostatic hypotension,\n* History of risk factors for Torsade de pointes (e.g., family history of Long QT Syndrome).\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O","description":"Detrusor Leak Point Pressure (LPP) was measured by cystometry.\n\nFor each measure, 2 or 3 cystometries were carried out depending on the difference between the 2 first LPP values (if the difference ≥ 20 cm H2O, a 3rd cystometry was done). The lowest value was retained.\n\nInvestigators reading was then consolidated by the review of all cystometry data by 2 external \"Expert Reviewers\", who were blinded for the study treatment.\n\nThe analysis was performed on consolidated investigators data (i.e. endorsed by the Investigator taking into account reviewers opinion).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Detrusor Leak Point Pressure (LPP)","description":"Detrusor Leak Point Pressure (LPP) was assessed at baseline and 12 weeks as described for the primary outcome measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":"12.6"},{"groupId":"OG001","value":"53.3","spread":"13.4"},{"groupId":"OG002","value":"50.9","spread":"10.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":"23.4"},{"groupId":"OG001","value":"41.6","spread":"18.2"},{"groupId":"OG002","value":"39.4","spread":"19.5"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Detrusor LPP","description":"Absolute change = Detrusor LPP at 12 weeks - Detrusor LPP at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"2.8"},{"groupId":"OG001","value":"-11.7","spread":"2.8"},{"groupId":"OG002","value":"-12.5","spread":"2.8"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Detrusor LPP","description":"Relative change = 100 \\* (Detrusor LPP at 12 weeks - Detrusor LPP at baseline) / Detrusor LPP at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"5.53"},{"groupId":"OG001","value":"-20.6","spread":"5.56"},{"groupId":"OG002","value":"-23.5","spread":"5.51"}]}]}]},{"type":"SECONDARY","title":"Detrusor Compliance","description":"Detrusor compliance is defined as the relationship between change in detrusor volume and change in detrusor pressure.\n\nIt was calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δpdet) during that change in detrusor volume at leak point (C= ΔV/Δpdet).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"2.8"},{"groupId":"OG001","value":"3.4","spread":"2.8"},{"groupId":"OG002","value":"3.3","spread":"2.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"5.0"},{"groupId":"OG001","value":"5.3","spread":"4.9"},{"groupId":"OG002","value":"5.8","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Detrusor Compliance","description":"Relative change = 100 \\* (Detrusor compliance at 12 weeks - Detrusor compliance at baseline) / Detrusor compliance at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.6","spread":"35.26"},{"groupId":"OG001","value":"126.6","spread":"35.76"},{"groupId":"OG002","value":"98.6","spread":"35.24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes","description":"When a patient presented with symptoms such as pain, fever or hematuria (discretion of the Investigator), an urinalysis was performed including a dipstick and a quantitative urine culture.\n\nA symptomatic UTI was defined as the presence of symptoms and a positive culture with \\> 100 000 Colony Forming Units (CFUs) with a single organism.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Symptomatic Urinary Tract Infection (UTI) Episodes","description":"Symptomatic UTI episodes were assessed similar to the previous outcome measure but for a longer follow-up period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":83},"commonTop":["NASOPHARYNGITIS","DIARRHOEA","PYREXIA","URINARY TRACT INFECTION","CYSTITIS"]}}}